In 79 patients with available MGMT promoter status in our study, 46 (58.2%) were methylated and 33 (41.8%) non‐methylated and the latter had a significant negative impact on OS and almost reached significance for PFS.
← all excerpts
Gliosarcoma: A Multi-Institutional Analysis on Clinical Outcomes and Prognostic Factors.
1
—
—